Immunovant Stock Today
| IMVT Stock | USD 19.52 0.73 3.89% |
PerformanceVery Weak
| Odds Of DistressAbout Average
|
Immunovant is selling for under 19.52 as of the 17th of March 2025; that is 3.89 percent increase since the beginning of the trading day. The stock's last reported lowest price was 18.7. Immunovant has 50 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 21st of June 2019 | Category Healthcare | Classification Health Care |
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 169.86 M outstanding shares of which 14.79 M shares are currently shorted by private and institutional investors with about 11.25 trading days to cover. More on Immunovant
Moving together with Immunovant Stock
| 0.65 | VRCA | Verrica Pharmaceuticals | PairCorr |
| 0.81 | ENVB | Enveric Biosciences Earnings Call This Week | PairCorr |
| 0.67 | EWTX | Edgewise Therapeutics | PairCorr |
Moving against Immunovant Stock
Follow Valuation Options Daily Balance Of Power
Check how we calculate scores
Immunovant Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsImmunovant can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Immunovant's financial leverage. It provides some insight into what part of Immunovant's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Immunovant (IMVT) is traded on NASDAQ Exchange in USA. It is located in 320 West 37th Street, New York, NY, United States, 10018 and employs 207 people. Immunovant is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.32 B. Immunovant conducts business under Biotechnology sector and is part of Health Care industry. The entity has 169.86 M outstanding shares of which 14.79 M shares are currently shorted by private and institutional investors with about 11.25 trading days to cover.
Immunovant currently holds about 427.2 M in cash with (214.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.66.
Check Immunovant Probability Of Bankruptcy
Ownership AllocationImmunovant has a total of 169.86 Million outstanding shares. Immunovant secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Also note that almost nine million five hundred ninety-seven thousand one hundred fourty-six invesors are currently shorting Immunovant expressing very little confidence in its future performance.
Check Immunovant Ownership Details
Immunovant Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Two Seas Capital Lp | 2024-12-31 | 1.5 M | |
| Viking Global Investors Lp | 2024-12-31 | 1.4 M | |
| Pictet Asset Manangement Sa | 2024-12-31 | 1.2 M | |
| Jpmorgan Chase & Co | 2024-12-31 | 1.2 M | |
| Hood River Capital Management Llc | 2024-12-31 | 1.1 M | |
| Stempoint Capital Lp | 2024-12-31 | 1.1 M | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1 M | |
| Franklin Resources Inc | 2024-12-31 | 984.1 K | |
| T. Rowe Price Associates, Inc. | 2024-12-31 | 916.2 K | |
| Fmr Inc | 2024-12-31 | 13.1 M | |
| Vanguard Group Inc | 2024-12-31 | 6.7 M |
Immunovant Historical Income Statement
Immunovant Stock Against Markets
Immunovant Corporate Management
| Jay Stout | Chief Officer | Profile | |
| Mark Levine | Chief Secretary | Profile | |
| Lauren MBA | Vice Marketing | Profile | |
| JD Esq | Chief Secretary | Profile | |
| Eva MBA | Chief Officer | Profile | |
| Julie Kirschling | Senior Management | Profile | |
| Christine Blodgett | Senior Resources | Profile |
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.